Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02572167
Title A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Seattle Genetics, Inc.

Hodgkin's lymphoma


Brentuximab vedotin + Nivolumab

Age Groups: adult
Covered Countries USA

No variant requirements are available.